諾誠健華-B(09969.HK):與渤健終止合作和許可協議 重獲奧布替尼全球權利
諾誠健華-B(09969.HK)公布,今日(15日)獲渤健通知,終止雙方就有望治療多發性硬化(MS)和其他自身免疫性疾病的口服小分子布魯頓酪氨酸激(酉每)(BTK)抑制劑奧布替尼的全球開發和商業化達成的合作和許可協議。
諾誠健華將重獲協議項下授予渤健的所有全球權利,包括相關知識產權、研發決策權、生產和商業化權益,以及源自奧布替尼的商業收益。雙方將在90天內完成權益過渡。
諾誠健華表示,歡迎奧布替尼重回公司的自身免疫性疾病管線;由於奧布替尼治療MS的II期研究仍在進行中,諾誠健華預計2023年第二季度公布中期分析結果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.